<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088642</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8735-109</org_study_id>
    <nct_id>NCT05088642</nct_id>
  </id_info>
  <brief_title>A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects</brief_title>
  <official_title>A Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in&#xD;
      subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic&#xD;
      impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with&#xD;
      normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">December 4, 2020</completion_date>
  <primary_completion_date type="Actual">December 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration vs time curve (AUC0-120).</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the blood concentration vs time curve (AUC0-inf).</measure>
    <time_frame>0-infinity</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Terminal Slope (t½)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to Day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sever Aplastic Anaemia</condition>
  <arm_group>
    <arm_group_label>Mild hepatic impairment (Child-Pugh Class A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment (Child-Pugh Class B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine Tablet</intervention_name>
    <description>Hetrombopag Olamine Tablet</description>
    <arm_group_label>Mild hepatic impairment (Child-Pugh Class A)</arm_group_label>
    <arm_group_label>Moderate hepatic impairment (Child-Pugh Class B)</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent form before the study and fully understand the study&#xD;
             content, process, and possible adverse reactions; able to complete the study as&#xD;
             required by the clinical study protocol;&#xD;
&#xD;
          2. Subjects (and their partners) are willing to adopt effective contraceptive measures&#xD;
             from screening to 6 months after the last study administration. See Appendix 1 for&#xD;
             specific contraceptive measures;&#xD;
&#xD;
          3. Aged 18-65 years (inclusive), male or female;&#xD;
&#xD;
          4. Body mass index (BMI = weight (kg)/height2 (m2)): 18-30 kg/m2 (inclusive);&#xD;
&#xD;
          5. For subjects with normal hepatic function: normal or abnormal but not clinically&#xD;
             significant laboratory findings (hematology, blood biochemistry, urinalysis, and&#xD;
             coagulation function);&#xD;
&#xD;
          6. For subjects with normal hepatic function: no history of severe primary disorders&#xD;
             involving major organs, including but not limited to the gastrointestinal,&#xD;
             respiratory, renal, hepatic, neural, hematological, endocrine, neoplastic,&#xD;
             immunological, psychiatric, or cardiovascular and cerebrovascular disorders.&#xD;
&#xD;
             Subjects with hepatic insufficiency must also meet the following inclusion criteria:&#xD;
&#xD;
          7. Have not received medication within 4 weeks before screening, or have received stable&#xD;
             medication for at least 4 weeks for hepatic impairment and/or other concurrent&#xD;
             diseases requiring long-term treatment;&#xD;
&#xD;
          8. With Child-Pugh Class A or B hepatic insufficiency caused by prior primary liver&#xD;
             disorders (except drug-induced liver diseases).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Average daily consumption of &gt; 5 cigarettes within 3 months before screening;&#xD;
&#xD;
          2. Allergic constitution, or allergy to any component of hetrombopag olamine tablets;&#xD;
&#xD;
          3. Average daily alcohol consumption of &gt; 15 g for females (e.g., 145 mL of wine, 497 mL&#xD;
             of beer, or 43 mL of low-alcohol liquor) and &gt; 25 g for males (e.g., 290 mL of wine,&#xD;
             994 mL of beer, or 86 mL of low-alcohol liquor) within 3 months before screening;&#xD;
&#xD;
          4. History of drug abuse within 3 months before screening;&#xD;
&#xD;
          5. Have donated or lost ≥ 400 mL of blood, or have received blood transfusion within 3&#xD;
             months before screening;&#xD;
&#xD;
          6. Have undergone major surgery within 6 months before screening, or with incomplete&#xD;
             healing of surgical incision;&#xD;
&#xD;
          7. History of deep vein thrombosis or other thromboembolic events, or clinical symptoms&#xD;
             suggesting thrombophilia;&#xD;
&#xD;
          8. Have received TPO receptor agonists (such as eltrombopag and romiplostim) or TPO&#xD;
             within 1 month before screening;&#xD;
&#xD;
          9. Have taken Chinese herbal medicines or any drug that affects the PK of hetrombopag&#xD;
             within 14 days before study administration (see Appendix 2 for drug-drug interaction&#xD;
             evaluation);&#xD;
&#xD;
         10. Hypertension [systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure&#xD;
             (DBP) ≥ 100 mmHg, confirmed by a re-measurement];&#xD;
&#xD;
         11. Female subjects who are in lactation or have a positive serum pregnancy test result at&#xD;
             screening or during the study;&#xD;
&#xD;
         12. Abnormal and clinically significant 12-lead ECG results (such as&#xD;
             tachycardia/bradycardia requiring pharmacological treatment, second- or third-degree&#xD;
             atrioventricular block or QTcF interval prolongation (≥ 470 ms for males, ≥ 480 ms for&#xD;
             females) (corrected according to Fridericia's formula), or other clinically&#xD;
             significant abnormalities assessed by the clinician);&#xD;
&#xD;
         13. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 calculated using the&#xD;
             Modification of Diet in Renal Disease (MDRD) equation;&#xD;
&#xD;
         14. Have malignant tumors or history of malignant tumors within 5 years before screening&#xD;
             (except treated non-melanoma skin cancer without sign of recurrence and resected&#xD;
             cervical intraepithelial neoplasia);&#xD;
&#xD;
         15. For subjects with normal hepatic function: have participated in any drug or medical&#xD;
             device clinical trials within 3 months before screening; for subjects with hepatic&#xD;
             insufficiency: have participated in any drug or medical device clinical trials within&#xD;
             1 month before screening;&#xD;
&#xD;
         16. For subjects with normal hepatic function: test positive for hepatitis B surface&#xD;
             antigen, hepatitis C antibody or hepatitis C core antigen, HIV antibody, or syphilis&#xD;
             antibody in screening;&#xD;
&#xD;
         17. Probably undergo surgery or be hospitalized during the study;&#xD;
&#xD;
         18. Have consumed alcohol (or positive for breath alcohol test), grapefruit/grapefruit&#xD;
             juice, or any food or beverage containing methylxanthine (such as coffee, tea, cola,&#xD;
             chocolate, and energy drink), have participated in strenuous physical activities, or&#xD;
             have other factors that may affect drug absorption, distribution, metabolism, and&#xD;
             excretion within 1 day before study administration;&#xD;
&#xD;
         19. Positive for urine drug screening (morphine or marijuana);&#xD;
&#xD;
         20. Subjects judged by the investigator as unsuitable for participating in this study.&#xD;
&#xD;
             Additional exclusion criteria for subjects with hepatic insufficiency (those who meet&#xD;
             any of the followings are ineligible):&#xD;
&#xD;
         21. History of liver transplant;&#xD;
&#xD;
         22. Liver failure, or liver cirrhosis complicated with hepatic encephalopathy,&#xD;
             hepatocellular carcinoma, esophageal and gastric varices hemorrhage, and other&#xD;
             complications that, in the opinion of the investigator, make subjects unsuitable for&#xD;
             participating in this study;&#xD;
&#xD;
         23. History of any serious diseases, other than primary liver diseases, or history of&#xD;
             disorders and/or clinically significant abnormal laboratory findings that, as judged&#xD;
             by the investigator, may affect the results of the study, including but not limited to&#xD;
             the history of diseases in the circulatory system, endocrine system, nervous system,&#xD;
             digestive system, urinary system or blood, immune, mental and metabolic diseases.&#xD;
&#xD;
         24. Positive for HIV antibody screening; a rapid plasma reagin (RPR) test is required for&#xD;
             a subject who tests positive for syphilis antibodies, and the subject should be&#xD;
             excluded if the RPR result is also positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

